LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 69

Search options

  1. Book ; Online ; E-Book: Paraproteinemia and related disorders

    Goubran, Hadi / Quartuccio, Luca / Ragab, Gaafar

    2022  

    Author's details editors : Gaafar Ragab, Luca Quartuccio, Hadi Goubran
    Keywords Plasma cell diseases ; Paraproteinemia/Diagnosis ; Paraproteinemia/Treatment
    Subject code 571.64
    Language English
    Size 1 online resource (398 pages)
    Publisher Springer
    Publishing place Cham, Switzerland
    Document type Book ; Online ; E-Book
    Note Includes index.
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 3-031-10131-6 ; 9783031101304 ; 978-3-031-10131-1 ; 3031101308
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book ; Online ; E-Book: The microbiome in rheumatic diseases and infection

    Ragab, Gaafar / Atkinson, T Prescott / Stoll, Matthew L.

    2018  

    Author's details Gaafar Ragab, T. Prescott Atkinson, Matthew L. Stoll editors
    Keywords Medicine ; Infectious diseases ; Rheumatology ; Pediatrics
    Subject code 616.723
    Language English
    Size 1 Online-Ressource (xxii, 490 Seiten), Illustrationen
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019760455
    ISBN 978-3-319-79026-8 ; 9783319790251 ; 3-319-79026-9 ; 3319790250
    DOI 10.1007/978-3-319-79026-8
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  3. Article: Metabolism-mediated thrombotic microangiopathy and B12.

    Goubran, Hadi / Ragab, Gaafar / Sabry, Waleed

    Vitamins and hormones

    2022  Volume 119, Page(s) 441–455

    Abstract: Thrombotic microangiopathies (TMAs) are a group of life-threatening conditions requiring urgent management and characterized by a clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and ischemic tissue injury. Severe vitamin B12 ( ... ...

    Abstract Thrombotic microangiopathies (TMAs) are a group of life-threatening conditions requiring urgent management and characterized by a clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and ischemic tissue injury. Severe vitamin B12 (Cobalamin-Cbl) deficiency or defective cobalamin metabolism, particularly defects in intracellular B12 metabolism, may lead to a TMA-like picture. The latter has been termed metabolism-mediated TMA (MM-TMA). This confusing picture is mediated partly by ineffective erythropoiesis with significant red cell fragmentation resulting in a hemolytic pattern, coupled with reduced platelet production and endothelial injury with organ damage resulting from accumulated toxic byproducts of B12 dysmetabolism. However, unlike in classic thrombotic thrombocytopenic purpura, where therapeutic plasma exchange has to be initiated promptly, cases of MM-TMA can be treated, if diagnosed properly, with adequate B12 replacement.
    MeSH term(s) Humans ; Purpura, Thrombotic Thrombocytopenic/diagnosis ; Purpura, Thrombotic Thrombocytopenic/drug therapy ; Thrombotic Microangiopathies/etiology ; Thrombotic Microangiopathies/therapy ; Vitamin B 12/therapeutic use
    Chemical Substances Vitamin B 12 (P6YC3EG204)
    Language English
    Publishing date 2022-02-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 201161-x
    ISSN 2162-2620 ; 0083-6729
    ISSN (online) 2162-2620
    ISSN 0083-6729
    DOI 10.1016/bs.vh.2022.01.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Blood transfusion in autoimmune rheumatic diseases.

    Goubran, Hadi / Ragab, Gaafar / Seghatchian, Jerard / Burnouf, Thierry

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2022  Volume 61, Issue 6, Page(s) 103596

    Abstract: Autoimmune rheumatic disorders (ARD) represent a wide spectrum of disorders that affect in priority the joints, bones, muscles, and connective tissues. Examples of ARD include rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, ... ...

    Abstract Autoimmune rheumatic disorders (ARD) represent a wide spectrum of disorders that affect in priority the joints, bones, muscles, and connective tissues. Examples of ARD include rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, polymyositis, systemic sclerosis, antiphospholipid syndrome and mixed connective tissue disease. Patients with ARD often require transfusion of red cell concentrates (RCC) or other blood-derived components. The presence of an autoimmune background, often complicated by the use of immunosuppressive medications, renders these patients quite vulnerable. Exposing them to RCC, when indicated, can trigger transfusion-related immunomodulation that can be aggravated by the role played by the donor microbiome, and the complement activation and the immune dysregulation induced by iron, leading to an amplification of the immune problems. Furthermore, patients are challenged by the transfused extracellular vesicles which could have a potentially negative role, particularly in patients with antiphospholipid syndrome. Despite the very vigorous screening, transfusion transmissible infections can still represent a risk to these patients, particularly in cytomegalovirus seronegative patients or when dormant pathogens are activated in the immunosuppressed transfusion recipient. The ARD population is also more at risk for transfusion-related reactions. One, therefore, has to consider a restrictive transfusion strategy if possible and, if needed, resort to the numerous blood bank procedures to reduce the immunogenicity of blood products or use safer, more targeted, industrial plasma-derived products subjected to purification and pathogen reduction technologies.
    MeSH term(s) Humans ; Antiphospholipid Syndrome ; Carcinoma, Renal Cell ; Autoimmune Diseases/drug therapy ; Arthritis, Rheumatoid ; Blood Transfusion/methods ; Kidney Neoplasms
    Language English
    Publishing date 2022-10-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2022.103596
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Platelet and extracellular vesicles in COVID-19 infection and its vaccines.

    Goubran, Hadi / Seghatchian, Jerard / Sabry, Waleed / Ragab, Gaafar / Burnouf, Thierry

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2022  Volume 61, Issue 3, Page(s) 103459

    Abstract: Platelets are at the crossroads between thrombosis and inflammation. When activated, platelets can shed bioactive extracellular vesicles [pEVs] that share the hemostatic potential of their parent cells and act as bioactive shuttles of their granular ... ...

    Abstract Platelets are at the crossroads between thrombosis and inflammation. When activated, platelets can shed bioactive extracellular vesicles [pEVs] that share the hemostatic potential of their parent cells and act as bioactive shuttles of their granular contents. In a viral infection, platelets are activated, and pEVs are generated with occasional virion integration. Both platelets and pEVs are engaged in a bidirectional interaction with neutrophils and other cells of the immune system and the hemostatic pathways. Severe COVID-19 infection is characterized by a stormy thromboinflammatory response with platelets and their EVs at the center stage of this reaction. This review sheds light on the interactions of platelets, pEVS and SARS-CoV-2 infection and prognostic and potential therapeutic role of pEVs. The review also describes the role of pEVs in the rare adenovirus-based COVID-19 vaccine-induced thrombosis thrombocytopenia.
    MeSH term(s) Blood Platelets/metabolism ; COVID-19 ; COVID-19 Vaccines ; Extracellular Vesicles/metabolism ; Hemostatics/metabolism ; Humans ; SARS-CoV-2 ; Thrombosis
    Chemical Substances COVID-19 Vaccines ; Hemostatics
    Language English
    Publishing date 2022-05-21
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2022.103459
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Autoinflammatory diseases and the kidney.

    Hegazy, Mohamed Tharwat / Fayed, Ahmed / Nuzzolese, Rossana / Sota, Jurgen / Ragab, Gaafar

    Immunologic research

    2023  Volume 71, Issue 4, Page(s) 578–587

    Abstract: The kidney represents an important target of systemic inflammation. Its involvement in monogenic and multifactorial autoinflammatory diseases (AIDs) vary from peculiar and relatively frequent manifestations to some rare but severe features that may end ... ...

    Abstract The kidney represents an important target of systemic inflammation. Its involvement in monogenic and multifactorial autoinflammatory diseases (AIDs) vary from peculiar and relatively frequent manifestations to some rare but severe features that may end up requiring transplantation. The pathogenetic background is also very heterogeneous ranging from amyloidosis to non-amyloid related damage rooted in inflammasome activation. Kidney involvement in monogenic and polygenic AIDs may present as renal amyloidosis, IgA nephropathy, and more rarely as various forms of glomerulonephritis (GN), namely segmental glomerulosclerosis, collapsing glomerulopathy, fibrillar, or membranoproliferative GN. Vascular disorders such as thrombosis or renal aneurysms and pseudoaneurysms may be encountered in patients with Behcet's disease. Patients with AIDs should be routinely assessed for renal involvement. Screening with urinalysis, serum creatinine, 24-h urinary protein, microhematuria, and imaging studies should be carried out for early diagnosis. Awareness of drug-induced nephrotoxicity, drug-drug interactions as well as addressing the issue of proper renal adjustment of drug doses deserve a special mention and should always be considered when dealing with patients affected by AIDs. Finally, we will explore the role of IL-1 inhibitors in AIDs patients with renal involvement. Targeting IL-1 may indeed have the potential to successfully manage kidney disease and improve long-term prognosis of AIDs patients.
    MeSH term(s) Humans ; Kidney/pathology ; Glomerulonephritis, IGA/pathology ; Amyloidosis/pathology ; Hereditary Autoinflammatory Diseases/diagnosis ; Hereditary Autoinflammatory Diseases/pathology ; Interleukin-1
    Chemical Substances Interleukin-1
    Language English
    Publishing date 2023-03-29
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 632857-x
    ISSN 1559-0755 ; 0257-277X
    ISSN (online) 1559-0755
    ISSN 0257-277X
    DOI 10.1007/s12026-023-09375-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: SARS-CoV-2 and cancer: the intriguing and informative cross-talk.

    Goubran, Hadi / Stakiw, Julie / Seghatchian, Jerard / Ragab, Gaafar / Burnouf, Thierry

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2022  Volume 61, Issue 4, Page(s) 103488

    Abstract: The COVID-19 pandemic caused by the SARS-CoV-2 virus has significantly disrupted and burdened the diagnostic workup and delivery of care, including transfusion, to cancer patients across the globe. Furthermore, cancer patients suffering from solid tumors ...

    Abstract The COVID-19 pandemic caused by the SARS-CoV-2 virus has significantly disrupted and burdened the diagnostic workup and delivery of care, including transfusion, to cancer patients across the globe. Furthermore, cancer patients suffering from solid tumors or hematologic malignancies were more prone to the infection and had higher morbidity and mortality than the rest of the population. Major signaling pathways have been identified at the intersection of SARS-CoV-2 and cancer cells, often leading to tumor progression or alteration of the tumor response to therapy. The reactivation of oncogenic viruses has also been alluded to in the context and following COVID-19. Paradoxically, certain tumors responded better following the profound infection-induced immune modulation. Unveiling the mechanisms of the virus-tumor cell interactions will lead to a better understanding of the pathophysiology of both cancer progression and virus propagation. It would be challenging to monitor, through the different cancer registries, retrospectively, the response of patients who have been previously exposed to the virus in contrast to those who have not contracted the infection.
    MeSH term(s) COVID-19 ; Humans ; Neoplasms/therapy ; Pandemics ; Retrospective Studies ; SARS-CoV-2
    Language English
    Publishing date 2022-06-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2022.103488
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Updates in cutaneous manifestations of systemic vasculitis.

    Elbendary, Amira / Abdel-Halim, Mona R E / Ragab, Gaafar

    Current opinion in rheumatology

    2021  Volume 34, Issue 1, Page(s) 25–32

    Abstract: Purpose of review: The main purpose of this review is to present newly reported cutaneous manifestations of systemic vasculitis, updates in investigations to verify systemic involvement in cases with cutaneous vasculitis and new therapeutic guidelines. ... ...

    Abstract Purpose of review: The main purpose of this review is to present newly reported cutaneous manifestations of systemic vasculitis, updates in investigations to verify systemic involvement in cases with cutaneous vasculitis and new therapeutic guidelines. The spectrum of COVID-19-related vasculitis is also covered.
    Recent findings: Only a few reports highlighted new cutaneous presentations or associations with some systemic vasculitic entities. For example, the association of inflammatory disorders with Takayasu arteritis, the importance of considering Kawasaki disease in febrile children with erythema nodosum, the development of necrotic ulcers on fingers and toes in Behçet's disease and the possible presence of polyarteritis nodosa-like pathological features in vulvar ulcers of Behçet's disease. New attempts to classify cutaneous manifestations of giant cell arteritis (GCA) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and the diagnostic investigations for cutaneous vasculitis cases to verify systemic involvement are discussed. Treatment of systemic vasculitis with cutaneous vasculitis should be tailored according to disease status. A plethora of reports in the past 2 years focused on the broad spectrum of COVID-19 vasculitic manifestations.
    Summary: Although newly reported cutaneous manifestations of systemic vasculitis are relatively uncommon, the plethora of reports in the past 2 years on COVID-19 vasculitis necessitates the expansion of the classification of vasculitis associated with probable cause to include severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) vasculitis.
    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ; COVID-19 ; Humans ; SARS-CoV-2 ; Skin Diseases, Vascular ; Takayasu Arteritis/complications ; Takayasu Arteritis/diagnosis
    Language English
    Publishing date 2021-09-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1045317-9
    ISSN 1531-6963 ; 1040-8711
    ISSN (online) 1531-6963
    ISSN 1040-8711
    DOI 10.1097/BOR.0000000000000847
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Vasculitic syndromes in hepatitis C virus

    Gaafar Ragab / Mohamed A. Hussein

    Journal of Advanced Research, Vol 8, Iss 2, Pp 99-

    A review

    2017  Volume 111

    Abstract: Vasculitis is a remarkable presentation of the extrahepatic manifestations of HCV. According to the presence or absence of cryoglobulins it is subdivided into two main types: cryoglobulinemic vasculitis and non cryoglobulinemic vasculitis based on the ... ...

    Abstract Vasculitis is a remarkable presentation of the extrahepatic manifestations of HCV. According to the presence or absence of cryoglobulins it is subdivided into two main types: cryoglobulinemic vasculitis and non cryoglobulinemic vasculitis based on the attribution of vasculitis to serum cryoglobulins as a pathogenic factor. The attribution of cryoglobulinemia to HCV represents a success story in the history of immunology, microbiology, and clinical medicine. HCV can bind to and invade lymphocytes, consequently triggering an immune response through different mechanisms. The epidemiology of the disease is well described and the clinical picture describes cutaneous, pulmonary, musculoskeletal, neurological, renal, endocrine, gastrointestinal, hepatic and cardiovascular manifestations. It may also be associated with sicca symptoms, an increased risk of lymphoma and serious catastrophic events. The pathology is well characterized. A classification criteria of the syndrome that was validated in 2014 is discussed. Management of CV is decided according to the presence and severity of its clinical presentation. It is divided into asymptomatic, mild, moderate, severe and life threatening disease. Recently introduced direct antiviral agents are proving safe and effective in the management of cryoglobulinemic vasculitis, and it is advocated that the two types of vasculitis be given prioritization in the Egyptian mass campaign to eradicate HCV.
    Keywords Hepatitis C virus ; Extrahepatic manifestations vasculitis ; Cryoglobulins ; Direct acting anti-HCV drugs ; Medicine (General) ; R5-920 ; Science (General) ; Q1-390
    Subject code 610
    Language English
    Publishing date 2017-03-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Rheumatologic manifestations of Hepatitis C Virus.

    Treppo, Elena / Quartuccio, Luca / Ragab, Gaafar / DE Vita, Salvatore

    Minerva medica

    2020  Volume 112, Issue 2, Page(s) 201–214

    Abstract: Introduction: Hepatitis C Virus (HCV) is a well-known worldwide infection, responsible for hepatic and extrahepatic complications. Among extrahepatic manifestation, the rheumatologic are the most common ones. With the arrival of Direct Antiviral Agents ( ...

    Abstract Introduction: Hepatitis C Virus (HCV) is a well-known worldwide infection, responsible for hepatic and extrahepatic complications. Among extrahepatic manifestation, the rheumatologic are the most common ones. With the arrival of Direct Antiviral Agents (DAA), the treatment and the clinical perspective have rapidly changed, permitting to achieve a sustained virological response (SVR) and preventing complications of chronic infection.
    Evidence acquisition: We performed on PubMed a literature search for the articles published by using the search terms "HCV infection," "HCV syndrome," "HCV-related rheumatologic disorders," "cryoglobulinemia," "cryoglobulinemic vasculitis" and "mixed cryoglobulinemia."
    Evidence synthesis: Mixed cryoglobulinemia (MC) is the prototype of HCV-associated rheumatologic disorder. HCV-related MC is typically considered by physicians as a human model disease to linking infection with autoimmune diseases. Chronic HCV infection can lead to a multistep process from a simple serological alteration (presence of circulating serum cryoglobulins) to frank systemic vasculitis (cryoglobulinemic vasculitis [CV]) and ultimately to overt malignant B lymphoproliferation (such as non-Hodgkin lymphoma [NHL]). Antiviral therapy is indicated to eradicate the HCV infection and to prevent the complications of chronic infection. Immunosuppressive therapy is reserved in case of organ threatening manifestations of CV. In this review, we discuss the main clinical presentation, diagnostic approach and treatment of rheumatologic manifestations of HCV infection.
    Conclusions: Chronic HCV infection is responsible for complex clinical condition, ranging from hepatic to extra-hepatic disorders. Cryoglobulins are the result of this prolonged immune system stimulation, caused by tropism of HCV for B-lymphocyte.
    MeSH term(s) Antiviral Agents/therapeutic use ; Arthralgia/etiology ; Cryoglobulinemia/diagnosis ; Cryoglobulinemia/etiology ; Cryoglobulinemia/prevention & control ; Cryoglobulins/immunology ; Hepacivirus/pathogenicity ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/diagnosis ; Hepatitis C, Chronic/drug therapy ; Humans ; Immunosuppression ; Kidney Diseases/etiology ; Lymphoma, Non-Hodgkin/etiology ; Muscle Weakness/etiology ; Purpura ; Sjogren's Syndrome/etiology ; Vasculitis/diagnosis ; Vasculitis/etiology ; Vasculitis/prevention & control
    Chemical Substances Antiviral Agents ; Cryoglobulins
    Language English
    Publishing date 2020-12-02
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 123586-2
    ISSN 1827-1669 ; 0026-4806
    ISSN (online) 1827-1669
    ISSN 0026-4806
    DOI 10.23736/S0026-4806.20.07158-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top